Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/full |
id |
doaj-461242d86c0c446297ab910c223fdce7 |
---|---|
record_format |
Article |
spelling |
doaj-461242d86c0c446297ab910c223fdce72020-11-24T22:54:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-11-01410.3389/fonc.2014.00334122788Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.Elda eTagliabue0Manuela eCampiglio1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan ItalyFondazione IRCCS Istituto Nazionale dei Tumori, Milan Italyhttp://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/fullomicsbreast cancertargeted therapyHER2Trastuzumab resistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elda eTagliabue Manuela eCampiglio |
spellingShingle |
Elda eTagliabue Manuela eCampiglio Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. Frontiers in Oncology omics breast cancer targeted therapy HER2 Trastuzumab resistance |
author_facet |
Elda eTagliabue Manuela eCampiglio |
author_sort |
Elda eTagliabue |
title |
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. |
title_short |
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. |
title_full |
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. |
title_fullStr |
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. |
title_full_unstemmed |
Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. |
title_sort |
omics and immunologic approaches to optimizing cure rates in her2-positive breast carcinomas. |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2014-11-01 |
topic |
omics breast cancer targeted therapy HER2 Trastuzumab resistance |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00334/full |
work_keys_str_mv |
AT eldaetagliabue omicsandimmunologicapproachestooptimizingcureratesinher2positivebreastcarcinomas AT manuelaecampiglio omicsandimmunologicapproachestooptimizingcureratesinher2positivebreastcarcinomas |
_version_ |
1725661404539650048 |